Market Cap 391.10M
Revenue (ttm) 236.20M
Net Income (ttm) -5.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 28.00
Profit Margin -2.27%
Debt to Equity Ratio 1.48
Volume 3,751,000
Avg Vol 3,314,462
Day's Range N/A - N/A
Shares Out 267.88M
Stochastic %K 82%
Beta 0.39
Analysts Strong Sell
Price Target $4.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
Tumblingtom
Tumblingtom Mar. 15 at 6:58 PM
$AKBA Next week, exciting yes? Will they get the sp down again? Or will we keep climbing? Shorts will have to make a choice. Think before you act!
1 · Reply
Akba_BO
Akba_BO Mar. 15 at 6:45 PM
$AKBA Convinced that biotech short sellers also torture puppies. Just saying.
0 · Reply
fresh10
fresh10 Mar. 15 at 6:27 PM
$AKBA SP predications for this week??......
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 15 at 4:52 PM
$AKBA LOSER, LOW LIFE, LYING, SHORTING, SCUM -
2 · Reply
ShadKilroy
ShadKilroy Mar. 15 at 4:23 PM
$AKBA this guy 🤡😂 lil fella shorting bottoms 🤣😂🤣😂🤪🙄🫃🏻all these short accounts with identical post language 🤥🤡🥸🥱🤖👾🤌
3 · Reply
Acemaker12
Acemaker12 Mar. 15 at 3:45 PM
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:23 PM
$AKBA So future is bright for Akebia if Sales team make their job to sell a great product and FDA will make proper decision All that’s said, I’m not a fan of John Butler but Akebia itself is more than promissing Good thinks take time
1 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:18 PM
$AKBA As well I belief that good Auryxia is going to stay longer so stable
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:15 PM
$AKBA Anway this are possible driver beside Fresenius will start to sell Vafeso as mentioned from JB this week. That would be amazing news and as well if Vafeso revenue will be increased significantly within the next quarters! This are vey realistic scenario for 2027
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:13 PM
$AKBA $AKBAJUST calculated the Potential if Vocal Phase IIIb by end of 2026 and as well Voice Phase IV by beginning of 2027 will be approved! Both have based on the previous safety test Results a probability to pass of around 80%! Of course FDA is final decision maker and that is impossible to predict This are vey realistic scenario for 2027
1 · Reply
Latest News on AKBA
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Jan 13, 2026, 1:21 PM EST - 2 months ago

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts


Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 3 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline


Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 3 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB


Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:01 AM EST - 4 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript


Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 4 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:44 PM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript


Tumblingtom
Tumblingtom Mar. 15 at 6:58 PM
$AKBA Next week, exciting yes? Will they get the sp down again? Or will we keep climbing? Shorts will have to make a choice. Think before you act!
1 · Reply
Akba_BO
Akba_BO Mar. 15 at 6:45 PM
$AKBA Convinced that biotech short sellers also torture puppies. Just saying.
0 · Reply
fresh10
fresh10 Mar. 15 at 6:27 PM
$AKBA SP predications for this week??......
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 15 at 4:52 PM
$AKBA LOSER, LOW LIFE, LYING, SHORTING, SCUM -
2 · Reply
ShadKilroy
ShadKilroy Mar. 15 at 4:23 PM
$AKBA this guy 🤡😂 lil fella shorting bottoms 🤣😂🤣😂🤪🙄🫃🏻all these short accounts with identical post language 🤥🤡🥸🥱🤖👾🤌
3 · Reply
Acemaker12
Acemaker12 Mar. 15 at 3:45 PM
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:23 PM
$AKBA So future is bright for Akebia if Sales team make their job to sell a great product and FDA will make proper decision All that’s said, I’m not a fan of John Butler but Akebia itself is more than promissing Good thinks take time
1 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:18 PM
$AKBA As well I belief that good Auryxia is going to stay longer so stable
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:15 PM
$AKBA Anway this are possible driver beside Fresenius will start to sell Vafeso as mentioned from JB this week. That would be amazing news and as well if Vafeso revenue will be increased significantly within the next quarters! This are vey realistic scenario for 2027
0 · Reply
Cmgi2712
Cmgi2712 Mar. 15 at 3:13 PM
$AKBA $AKBAJUST calculated the Potential if Vocal Phase IIIb by end of 2026 and as well Voice Phase IV by beginning of 2027 will be approved! Both have based on the previous safety test Results a probability to pass of around 80%! Of course FDA is final decision maker and that is impossible to predict This are vey realistic scenario for 2027
1 · Reply
Yamauchii
Yamauchii Mar. 15 at 2:50 PM
$AKBA @Holy_boy One question sir: 50% eligible patients means 50% TDAPA patients right?
1 · Reply
Holy_boy
Holy_boy Mar. 15 at 1:29 PM
$AKBA @hsainu This is Feb letter. March has not come out yet. The concomitant rescue epo use policy is largely due to my effort. The TIW use has finally been implemented in my unit with 25% increase in # of pts.
7 · Reply
Ketchy
Ketchy Mar. 15 at 1:39 AM
$AKBA the chart looks less crap
1 · Reply
Tumblingtom
Tumblingtom Mar. 14 at 7:55 PM
$AKBA Shortinterest is falling, very interesting to see the coming weeks. Early may is getting closer so fingers crossed. Glta 🤞
1 · Reply
AceofSavage
AceofSavage Mar. 14 at 7:28 PM
$AKBA This will be $2+ in April. If it isn't then I will not message on this board until the price is $2. :)
2 · Reply
Brb5010
Brb5010 Mar. 14 at 7:17 PM
$AKBA are we still hoping for 20 mil Q1 revenue for Vafseo? Or has the bar been set higher? I, like many of you, think Auryxia is going to hold off generics longer than anticipated (which is much needed at this time)
3 · Reply
PharmaExpert
PharmaExpert Mar. 14 at 7:17 PM
$AKBA is it monday yet!🔥
1 · Reply
Noname2022
Noname2022 Mar. 14 at 6:50 PM
$CRMD $AKBA $FMS $DVA GovTrack currently shows about a 3% chance of enactment for the bill. Worth noting: Rep. Mike Kelly joined as a cosponsor on Jan 30 and sits on the House Ways & Means Health Subcommittee, the committee responsible for Medicare dialysis policy and the upcoming kidney hearing.
5 · Reply
KarlDieGlatze
KarlDieGlatze Mar. 14 at 4:50 PM
$AKBA Akebia Therapeutics and Cyclerion Therapeutics amended their license agreement in December 2024, securing $1.75 million in immediate payments for Cyclerion to support Akebia's development of praliciguat for rare kidney diseases. Akebia is advancing praliciguat for focal segmental glomerulosclerosis (FSGS) with a Phase 2 trial, with potential total milestone payments to Cyclerion exceeding $560 million.
1 · Reply
CustomCulture
CustomCulture Mar. 14 at 4:34 PM
$AKBA My models remain firmly bullish on Akebia Therapeutics. The technical breakout we were waiting for has now been achieved, confirming the accumulation pattern many of us suspected over the past months. Price action and volume suggest stronger hands have been positioning while retail was shaken out. With the breakout now validated, my models update to 3x-4x the current PPS as a reasonable mid-term target if momentum and fundamentals continue aligning. Breakout + accumulation + rising narrative = the setup is getting stronger, not weaker. Shorts should be careful here. GLTA
1 · Reply
Dipwhits
Dipwhits Mar. 14 at 3:39 PM
$AKBA Swing setup I'm watching. After a long selloff the stock is sitting near clear support around $1.35–$1.40. These beaten-down biotech charts often bounce when they stabilize at support. Entry zone: $1.40–$1.48 Risk level: break below ~$1.30 Targets: $1.70 → $1.90 → $2.20 if momentum builds This isn’t a long-term hold setup — it’s a technical bounce trade. If support holds, a relief move back into the $1.70s–$1.90s is very realistic. This is not advice
1 · Reply
Cmgi2712
Cmgi2712 Mar. 14 at 3:16 PM
$AKBA This month will be a bullish month
1 · Reply